“Enzastaurin For The Treatment Of Cancer”

Abstract: The present invention relates to HDAC2 as a biological marker for treating cancer in a patient using Enzastaurin as a single agent or in combination with a Class I selective HDAC inhibitor.

Patent Information

Application #

Filing Date

15 June 2011

Publication Number

39/2012

Publication Type

INA

Invention Field

PHARMACEUTICALS

Status

Email

Parent Application

Applicants

ELI LILLY AND COMPANY

Lilly Corporate Center City of Indianapolis State of Indiana 46285 United States of America.

Inventors

1. Gopinath GANJI

c/o Eli Lilly and Company Lilly Corporate Center Indianapolis Indiana 46285 U.S.A.

Specification

PLEASE SEE THE SPECIFICATION ATTACHED.

Documents

Application Documents

#	Name	Date
1	4243-CHENP-2011 FORM-18 20-06-2011.pdf	2011-06-20
1	4243-CHENP-2011-AbandonedLetter.pdf	2017-10-06
2	4243-CHENP-2011 FORM-13 20-06-2011.pdf	2011-06-20
2	4243-CHENP-2011-FER.pdf	2017-03-31
3	Form-1.pdf	2011-09-04
3	4243-CHENP-2011 CORRESPONDENCE OTHERS 20-06-2011.pdf	2011-06-20
4	Form-3.pdf	2011-09-04
4	4243-CHENP-2011 FORM-3 29-06-2011..pdf	2011-06-29
5	4243-CHENP-2011 CORRESPONDENCE OTHERS 29-06-2011..pdf	2011-06-29
5	Form-5.pdf	2011-09-04
6	4243-CHENP-2011 CORRESPONDENCE OTHERS 14-07-2011.pdf	2011-07-14
7	4243-CHENP-2011 CORRESPONDENCE OTHERS 29-06-2011..pdf	2011-06-29
7	Form-5.pdf	2011-09-04
8	4243-CHENP-2011 FORM-3 29-06-2011..pdf	2011-06-29
8	Form-3.pdf	2011-09-04
9	4243-CHENP-2011 CORRESPONDENCE OTHERS 20-06-2011.pdf	2011-06-20
9	Form-1.pdf	2011-09-04
10	4243-CHENP-2011-FER.pdf	2017-03-31
10	4243-CHENP-2011 FORM-13 20-06-2011.pdf	2011-06-20
11	4243-CHENP-2011-AbandonedLetter.pdf	2017-10-06
11	4243-CHENP-2011 FORM-18 20-06-2011.pdf	2011-06-20

Search Strategy

1	SEARCHSRATEGY_23-03-2017.pdf